Veklury significantly reduced risk of hospitalization in high-risk patients with COVID-19 – Gilead Sciences

Gilead Sciences, Inc. announced positive results from a Phase III randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of a three-day course of Veklury(remdesivir) for intravenous (IV) use for the treatment of COVID-19 in non-hospitalized patients at high risk for disease progression . This late-breaking data will be presented at the IDWeek 2021 virtual conference. In an analysis […]